INCA33890: Clinical Trials

3 recruiting, 2 not yet recruiting. 2 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Not yet recruiting	Groupe Oncologie Radiotherapie Tete et Cou	78	2027-02-01	2026-10-22
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer)	Phase 2	Not yet recruiting	Incyte Corporation	40	2026-10-26	2026-09-22
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer INCA33890, Placebo, Bevacizumab - CRC (Colorectal Cancer)	Phase 3	Recruiting	Incyte Corporation	700	2026-03-05	2026-10-30
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734, Cetuximab, Retifanlimab - Solid Tumors	Phase 1	Recruiting	Incyte Corporation	710	2024-01-04	2026-07-22
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors INCA33890, bevacizumab, FOLFIRI - Solid Tumors, Advanced Solid Tumors	Phase 1	Recruiting	Incyte Corporation	570	2023-07-24	2026-07-23